http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#Head http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#assertion http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#provenance http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#pubinfo http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#assertion http://purl.obolibrary.org/obo/DOID_9253 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9253 http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00619 http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association http://www.w3.org/2000/01/rdf-schema#label gleevec is a kinase inhibitor indicated for the treatment of newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase 1 1 patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in blast crisis bc accelerated phase ap or in chronic phase cp after failure of interferon alpha therapy 1 2 adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all 1 3 pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia ph all in combination with chemotherapy 1 4 adult patients with myelodysplastic myeloproliferative diseases mds mpd associated with pdgfr platelet derived growth factor receptor gene re arrangements as determined with an fda approved test 1 5 adult patients with aggressive systemic mastocytosis asm without the d816v c kit mutation as determined with an fda approved test or with c kit mutational status unknown 1 6 adult patients with hypereosinophilic syndrome hes and or chronic eosinophilic leukemia cel who have the fip1l1 pdgfri fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes and or cel who are fip1l1 pdgfri fusion kinase negative or unknown 1 7 adult patients with unresectable recurrent and or metastatic dermatofibrosarcoma protuberans dfsp 1 8 patients with kit cd117 positive unresectable and or metastatic malignant gastrointestinal stromal tumors gist 1 9 adjuvant treatment of adult patients following resection of kit cd117 positive gist 1 1 newly diagnosed adult and pediatric patients with philadelphia chromosome positive chronic myeloid leukemia ph cml in chronic phase patients with philadelphia chromosome positive chronic myeloid leukemia in blast crisis accelerated phase or in chronic phase after failure of interferon alpha therapy adult patients with relapsed or refractory philadelphia chromosome positive acute lymphoblastic leukemia ph all pediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia ph all in combination with chemotherapy adult patients with myelodysplastic myeloproliferative diseases associated with pdgfr platelet derived growth factor receptor gene re arrangements as determined with an fda approved test see dosage and administration 2 6 adult patients with aggressive systemic mastocytosis without the d816v c kit mutation as determined with an fda approved test see dosage and administration 2 7 adult patients with hypereosinophilic syndrome and or chronic eosinophilic leukemia who have the fip1l1 pdgfri fusion kinase mutational analysis or fish demonstration of chic2 allele deletion and for patients with hes and or cel who are fip1l1 pdgfri fusion kinase negative or unknown adult patients with unresectable recurrent and or metastatic dermatofibrosarcoma protuberans patients with kit cd117 positive unresectable and or metastatic malignant gastrointestinal stromal tumors adjuvant treatment of adult patients following complete gross resection of kit cd117 positive gist http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00619 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#provenance http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#pubinfo http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#sig http://purl.org/nanopub/x/hasSignature ZRbmjttYz8/8fNcz+7/9vPZbPlUEBMHVj2RfroMZeneTxeq0qDiyznP+cpfatpOaEfoJErLAbm3/76sGTQRmtN1TJPWvmRWQWoDZYEvOaghUUttkN6wO3FB4WN31PkNQo3rVt2h1JMGOOs328V13DMXZsVokEzJZgQWM8dvCWX4= http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM http://purl.org/dc/terms/created 2021-07-03T14:18:50.693+02:00 http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA1n2_1vGZ6W4t01zeh-MlMRwDEFNUbBQaae81j0BEZxM https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs